72 related articles for article (PubMed ID: 22139601)
1. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study.
Ahn YM; Lee KY; Kim CE; Kang DY; Seok JH; Shin YM; Chung IW; Jun TY; Chang JS; Kim YS
Hum Psychopharmacol; 2011 Dec; 26(8):568-77. PubMed ID: 22139601
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
4. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.
Linden M; Scheel T; Xaver Eich F
Hum Psychopharmacol; 2004 Mar; 19(2):111-9. PubMed ID: 14994321
[TBL] [Abstract][Full Text] [Related]
5. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
6. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Lee SJ; Lee JH; Jung SW; Koo BH; Choi TY; Lee KH
Clin Drug Investig; 2012 Nov; 32(11):735-45. PubMed ID: 23018281
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
8. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
[TBL] [Abstract][Full Text] [Related]
11. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.
Rabinowitz J; Napryeyenko O; Burba B; Martinez G; Neznanov NG; Fischel T; Baylé FJ; Cavallaro R; Smeraldi E; Schreiner A
J Clin Psychopharmacol; 2011 Feb; 31(1):75-81. PubMed ID: 21192147
[TBL] [Abstract][Full Text] [Related]
12. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
[TBL] [Abstract][Full Text] [Related]
13. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
Baddoura R; Ourgandjian H
J Med Liban; 2004; 52(2):78-85. PubMed ID: 15884686
[TBL] [Abstract][Full Text] [Related]
14. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Blin O
Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
[TBL] [Abstract][Full Text] [Related]
15. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
Rzewuska M; Kuczyński W; Luks M
Psychiatr Pol; 2004; 38(3):453-68. PubMed ID: 15199655
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
19. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
Psarros C; Theleritis CG; Paparrigopoulos TJ; Politis AM; Papadimitriou GN
Int J Geriatr Psychiatry; 2009 May; 24(5):518-22. PubMed ID: 19072747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
